Lung Cancer

Edit Your Profile

Lung Cancer Journal

publication venue for

Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). 160:92-98. 2021
Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. 155:183-190. 2021
Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. 111:84-87. 2017
Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. 90:78-84. 2015
A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. 81:416-421. 2013
Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). 53:347-353. 2006
Pemetrexed-associated urticarial vasculitis. 51:247-249. 2006
P-128 Establishment and characterization of a line of transgenic miceharboring a lung specific human type II p53(175H) mutation; a potential model of human disease. 49:s148. 2005
E-53. Helical tomotherapy: An innovative technological radiation therapeutic approach for lung cancer. 41:s67-s68. 2003
O-125 ECOG 2597: Phase III study of induction chemotherapy followed by standard thoracic radiotherapy (STD TRT) vs hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage III A & B non-small cell lung cancer. 41:s39. 2003
O-22 Megavoltage CT imaging for image-guided lung cancer intensity modulated radiation therapy (IMRT). 41:s10. 2003
O-66 Impact of whole brain radiation therapy (WBRT) and motexafin gadolinium (MGd) on neurologic and neurocognitive progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a randomized phase III trial. 41:s22. 2003
P-465 Differences in baseline characteristics between non-small cell lung cancer (NSCLC) and breast cancer (BrCa) patients with brain metastases. 41:s208-s209. 2003
Differential expression and biodistribution of cytokeratin 18 and desmoplakins in non-small cell lung carcinoma subtypes. 36:133-141. 2002
481 ECOG 4593: Phase II hyperfractionated accelerated radiotherapy (HART) for non small cell lung cancer (NSCLC): Early results and RT quality assurance (QA). 18:123. 1997
Technical and biological aspects of optically guided extra cranial stereotactic radiotherapy for pheripheral T1/T2N0M0 NSC lung tumors 2005
A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies 2004
Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer - Experience from a prematurely closed phase II study [5] 2004
The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments 2018
Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation 2014

International Standard Serial Number (ISSN)

0169-5002

Electronic International Standard Serial Number (EISSN)

1872-8332